<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100955</url>
  </required_header>
  <id_info>
    <org_study_id>QU20170327</org_study_id>
    <nct_id>NCT03100955</nct_id>
  </id_info>
  <brief_title>A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer</brief_title>
  <official_title>A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the progression free survival in patients with extensive stage small cell lung
      cancer treated with cisplatin and etoposide plus or not apatinib
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess progression free survival, overall survival and toxicity of standard EP regimen
      combined or not with VEGF tyrosine kinase inhibitor-apatinib. Response measured by RECIST
      response criteria. Toxicity via physical exam, adverse event review, assessing signs and
      symptoms, quality of life assessment and blood testing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>24 months</time_frame>
    <description>from the date of randomization to disease progression</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Progression Free Survival</condition>
  <arm_group>
    <arm_group_label>EP chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment or active comparator group contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EP chemotherapy plus apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib treatment or experimental group contains standard chemotherapy and apatinib, a VEGF tyrosine kinase inhibitor. It contains a platinum drug, a topoisomerase inhibitor and a VEGF-TKI. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI=apatinib, 500 mg, oral daily after chemotherapy, until disease progression or death or un-tolerated toxicites. Used drugs=cisplatinum and etoposide and apatinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin, etoposide</intervention_name>
    <description>The recommended regimen is cisplatin plus etoposide. cisplatin 75 mg/m2 iv on day 1, etoposide 120 mg/m2 iv on day 1-3, 3 weeks a cycle, total for 6 cycles is allowed.</description>
    <arm_group_label>EP chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin, etoposide, apatinib</intervention_name>
    <description>Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatin and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI apatinib oral daily after chemotherapy treatment. Apatinib 500mg oral, once a day, until disease progression or death or un-tolerated toxicites.</description>
    <arm_group_label>EP chemotherapy plus apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically verified SCLC, extensive stages

          2. WHO performance status 0, 1, 2

          3. Age 18 years or older

          4. Treatment naive

          5. Anticipated survival more than 3 months

          6. HB &gt;90g/L, ANC&gt;1.5 x 109/L, Platelets &gt;80 x109 /L

          7. No prognancy

          8. Signed informed consent

        Exclusion Criteria:

          1. Limited stage disease

          2. Metastastic meningitis, spinal compression, Tumor to main vesicular less than 5mm

          3. Uncontrolled hypertension

          4. Uncontrolled heart failure

          5. Coagulation problem

          6. Surgery, trauma, uncontrolled ulcer in 4 weeks.

          7. Required by physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhuang Yu, MD, Ph. D</last_name>
    <role>Study Chair</role>
    <affiliation>Affiliated hospital of Qingdao University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>keke nie, MD</last_name>
    <phone>(86)18561857907</phone>
    <email>niekekeqd@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>youxin ji, MD, Ph. D</last_name>
    <phone>(86)532-68665078</phone>
    <email>ji6677@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuang Yu, MD</last_name>
      <phone>(86)18661805688</phone>
      <email>yuzhuang2002@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhuang Yu, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qingdao University</investigator_affiliation>
    <investigator_full_name>medley nie</investigator_full_name>
    <investigator_title>Secretary of clinical trials</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Topoisomerase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

